Open access
Jul 2026
Combination of proton-pump inhibitor and anti-CD3 F(ab’)2 for islet neogenesis and immune modulation in type 1 diabetes
A combination therapy integrating a proton pump inhibitor with a non–Fc-binding anti-CD3 F(ab’)2 antibody fragment to concurrently promote β-cell neogenesis and modulate autoimmune T-cell responses achieved sustained glycemic control in T1D models.
Tung-Yun Wu, Che-Yi Chen, Michael Chen et al.
· Immunotherapy Advances · 0 citations